CHRONIC MYELOID LEUKAEMIA research identifies PELI1 as a central regulator of disease progression and a promising therapeutic target capable of overcoming resistance to current treatments.
PELI1 in Chronic Myeloid Leukaemia
Chronic myeloid leukaemia is driven by BCR-ABL1, a fusion gene arising from structural chromosome rearrangements that underpins malignant transformation. While targeting BCR-ABL1 degradation represents an ideal therapeutic strategy, the regulatory mechanisms controlling its expression have remained unclear. New findings demonstrate that PELI1 plays a critical role in maintaining BCR-ABL1 levels in chronic myeloid leukaemia. The data show that BCR-ABL1 upregulates PELI1 through the STAT5 and FOXP3 signalling pathway. In turn, PELI1 interacts directly with BCR-ABL1, protecting it from degradation within leukaemic cells.
Mechanistic Insights into Disease Progression
Beyond stabilising BCR-ABL1, PELI1 also functions as a downstream effector that promotes cellular proliferation in chronic myeloid leukaemia. This dual role highlights its importance in sustaining both oncogenic signalling and disease progression. The study findings indicate that PELI1 is not merely a passive regulator but an active contributor to the expansion of malignant cells. By maintaining BCR-ABL1 expression and supporting proliferative signalling, PELI1 reinforces the pathological framework of chronic myeloid leukaemia.
Therapeutic Potential of Targeting PELI1
Importantly, inhibition of PELI1, either through genetic approaches or pharmacological intervention, significantly suppresses proliferation across multiple disease contexts. These include cells that remain sensitive to tyrosine kinase inhibitors and those that exhibit resistance. Furthermore, inhibition of PELI1 effectively targets leukaemia stem cells, which are often implicated in disease persistence and relapse. The data suggest that reducing PELI1 activity leads to a marked decrease in disease burden and slows progression of chronic myeloid leukaemia.
Collectively, these findings position PELI1 as a promising therapeutic target. Strategies aimed at disrupting PELI1 function may offer a means to overcome resistance to existing treatments while addressing the challenge of eradicating leukaemia stem cells. This approach could represent a significant advance in the management of chronic myeloid leukaemia.
Reference
Zhou Q et al. Inhibition of Pellino-1 reverts the progression and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Cell Death & Disease. 2026; https://doi.org/10.1038/s41419-026-08799-7.
Featured image: TensorSpark on Adobe Stock.
